tiprankstipranks
Trending News
More News >
Noumi Limited (AU:NOU)
ASX:NOU
Australian Market

Noumi Limited (NOU) AI Stock Analysis

Compare
4 Followers

Top Page

AU:NOU

Noumi Limited

(Sydney:NOU)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 4o)
Rating:40Underperform
Price Target:
AU$0.12
▼(-8.46% Downside)
Noumi Limited's overall stock score is primarily impacted by its weak financial performance and valuation. The company's high leverage and negative equity pose significant risks, while the negative P/E ratio reflects ongoing profitability challenges. Technical indicators suggest a bearish trend, further weighing on the stock's outlook.
Positive Factors
Product Innovation
Noumi's focus on innovation in health and wellness solutions positions it well to capture growing consumer demand for natural products, supporting long-term growth.
Distribution Partnerships
Strong distribution partnerships expand market reach and customer base, enhancing revenue potential and supporting sustained business growth.
Cash Flow Management
Improved cash flow management indicates better operational efficiency, which can enhance financial stability and support future investments.
Negative Factors
High Leverage
High leverage and negative equity pose risks to financial stability, potentially limiting growth opportunities and increasing vulnerability to economic shifts.
Profitability Challenges
Ongoing profitability challenges, reflected in negative margins, may hinder the company's ability to reinvest in growth and innovation.
Volatile Revenue Growth
Inconsistent revenue growth indicates potential market or operational challenges, which could impact long-term financial planning and stability.

Noumi Limited (NOU) vs. iShares MSCI Australia ETF (EWA)

Noumi Limited Business Overview & Revenue Model

Company Descriptionnoumi Limited engages in sourcing, manufacture, selling, marketing, and distribution of plant-based beverages, and dairy and nutritional ingredient products to wholesale and consumer markets. It operates in Dairy and Nutritional, and Plant Based Beverages segments. The company offers a range of ultra-heat treatment technology (UHT) shelf stable dairy milk beverage, nutritional products, and performance and adult nutritional powders. It also provides various UHT shelf stable food and beverage products, including almond, oat, soy, rice, coconut, hazelnut, and other nut-based beverages and liquid stocks. The company provides its products under the Milklab, Australia's Own, Crankt, Vital Strength, Noumi Nutritionals, Uproteinn, So Natural, and Vitalife brands. It operates in Australia, New Zealand, South Africa, China, South East Asia, and the Middle East. noumi Limited was formerly known as Freedom Foods Group Limited. The company was incorporated in 1984 and is headquartered in Ingleburn, Australia. noumi Limited is a subsidiary of Arrovest Pty Limited.
How the Company Makes MoneyNoumi Limited generates revenue through the sale of its core products, which include dietary supplements and functional foods. The company's revenue model primarily relies on direct sales to consumers via e-commerce platforms and retail partnerships. Key revenue streams include product sales, subscriptions for regular deliveries of health products, and collaborations with health professionals and fitness centers. Significant partnerships with retailers and online marketplaces enhance its distribution capabilities, driving customer acquisition and increasing sales volume. Additionally, Noumi Limited's focus on brand loyalty and customer retention through high-quality products and customer engagement strategies contributes to its earnings.

Noumi Limited Financial Statement Overview

Summary
Noumi Limited faces significant financial challenges, with a negative net profit margin and declining EBITDA margin. The balance sheet shows high leverage and negative equity, indicating financial instability. While there are some positive trends in cash flow management, overall financial health is concerning.
Income Statement
45
Neutral
Noumi Limited has shown some improvement in its gross profit margin over the years, reaching 27.14% in 2025, indicating better cost management. However, the company continues to face challenges with profitability, as evidenced by a negative net profit margin of -25.18% and a declining EBITDA margin. Revenue growth has been inconsistent, with a notable increase in 2025, but past fluctuations suggest volatility in sales performance.
Balance Sheet
30
Negative
The balance sheet reveals significant financial instability, with a negative stockholders' equity indicating potential solvency issues. The debt-to-equity ratio is negative, reflecting high leverage and financial risk. Although there is a slight improvement in return on equity, the overall financial health remains concerning due to persistent negative equity.
Cash Flow
40
Negative
Cash flow analysis shows some positive trends, such as a reduction in negative free cash flow and an improvement in operating cash flow. However, the operating cash flow to net income ratio remains low, indicating challenges in converting income into cash. The free cash flow to net income ratio is relatively high, suggesting some efficiency in cash management despite overall financial struggles.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue595.84M595.84M589.79M551.56M522.34M547.29M
Gross Profit161.72M161.72M145.75M134.77M98.42M93.53M
EBITDA49.20M-132.09M-61.24M-6.37M-122.53M28.01M
Net Income-150.00M-150.00M-98.33M-46.91M-160.74M-53.18M
Balance Sheet
Total Assets265.17M265.17M316.20M377.95M420.13M538.67M
Cash, Cash Equivalents and Short-Term Investments23.18M23.18M21.57M18.56M16.21M31.67M
Total Debt614.75M614.75M533.76M491.00M455.01M462.39M
Total Liabilities717.51M717.51M621.14M581.49M569.14M537.18M
Stockholders Equity-452.34M-452.34M-304.94M-203.54M-149.01M1.49M
Cash Flow
Free Cash Flow27.66M27.66M11.02M-49.00K-46.87M-56.67M
Operating Cash Flow32.52M32.52M15.83M4.31M-40.86M-54.01M
Investing Cash Flow2.09M2.09M1.84M2.22M-3.93M13.50M
Financing Cash Flow-33.01M-33.01M-21.64M-4.18M29.33M53.80M

Noumi Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.13
Price Trends
50DMA
0.13
Negative
100DMA
0.14
Negative
200DMA
0.14
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
39.12
Neutral
STOCH
-13.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NOU, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.12 is Neutral, neither overbought nor oversold. The STOCH value of -13.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NOU.

Noumi Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
45
Neutral
AU$22.56M-5.56-29.43%102.21%69.47%
43
Neutral
AU$33.11M39.136.76%
40
Underperform
AU$36.02M-0.231.03%-52.56%
38
Underperform
AU$27.50M-5.00-20.54%13.92%36.28%
38
Underperform
AU$7.70M-0.20-184.71%39.53%49.99%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:NOU
Noumi Limited
0.12
-0.05
-29.41%
AU:AHF
Australian Dairy Nutritionals Group
0.04
-0.02
-32.08%
AU:WNX
Wellnex Life Ltd
0.10
-0.57
-85.07%
AU:NUC
Nuchev Pty Ltd
0.14
0.02
16.67%
AU:HCT
Holista Colltech Limited
0.09
0.08
800.00%

Noumi Limited Corporate Events

Noumi Limited Issues Unquoted Equity Securities for Employee Incentive
Nov 27, 2025

Noumi Limited has announced the issuance of unquoted equity securities, specifically options expiring on September 11, 2027, with a total of 1,504,348 securities issued. This move is part of an employee incentive scheme and is not intended for quotation on the ASX. The issuance of these securities reflects Noumi Limited’s strategic efforts to incentivize its workforce, potentially impacting its operational dynamics and aligning employee interests with company performance.

Noumi Limited Extends CEO’s Contract for Continued Leadership Stability
Nov 16, 2025

Noumi Limited has announced a change to CEO Michael Perich’s contract, extending it from a fixed term ending December 2025 to an open-ended term. This change aims to provide leadership stability as Mr. Perich has been instrumental in leading the company’s transformation program since August 2020, with the board expecting this move to support the completion of the program and ensure long-term sustainable growth.

Noumi Limited’s 2025 AGM Resolutions Successfully Passed
Nov 6, 2025

Noumi Limited announced the successful outcomes of its 2025 Annual General Meeting, where all proposed resolutions were approved by poll. Key resolutions included the adoption of the Remuneration Report, re-election of directors Anthony Perich AM and Jane Mckellar, approval of the Noumi Equity Incentive Plan, and renewal of Proportional Takeover Provisions. These approvals are expected to support Noumi’s strategic initiatives and strengthen its governance framework, potentially enhancing its market position and stakeholder confidence.

Noumi Limited Releases 2025 AGM Presentation and Addresses
Nov 6, 2025

Noumi Limited has released its 2025 Annual General Meeting presentation and addresses, indicating a strategic focus on its core offerings in the dairy and plant-based beverage market. This announcement underscores Noumi’s commitment to maintaining its leadership position in the FMCG sector by leveraging its state-of-the-art manufacturing capabilities and diverse product portfolio.

Noumi Limited Reports Strong Q1 FY26 Revenue Growth Amidst Legal Settlements
Oct 31, 2025

Noumi Limited reported a 9% increase in consolidated revenue for Q1 FY26, reaching $162.4 million. The company’s plant-based milks segment experienced a slight decline due to lower contract manufacturing revenues, while the dairy and nutritionals segment saw significant growth. Noumi’s cash flow was positively impacted by a $12.8 million operating cash flow, despite legal expenses. The company successfully settled legacy legal matters and maintained a strong cash position with $21.9 million in unrestricted cash and $10 million in undrawn facilities. Noumi is preparing for the maturity of its Convertible Notes in 2027, with a current redemption value of $597.4 million.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 01, 2025